Ropes & Gray advised Novo Nordisk in expanding its collaboration with Valo Health in a deal worth up to $4.6 billion to discover and develop new treatments using artificial intelligence and real-world patient data to develop up to 20 treatments for obesity, type 2 diabetes and cardiovascular disease. The deal was announced on January 8.
In 2023, Ropes & Gray advised Novo Nordisk in forming a Valo partnership with an 11-program collaboration focused on cardiovascular disease. That collaboration was worth up to $2.7 billion in milestones, plus research and development funding and potential royalty payments.
Under the expanded agreement, Valo is entitled to receive an upfront payment, equity investment and potential near-term milestone payments totaling $190 million and is eligible to receive milestone payments for up to 20 drug programs, totaling approximately $4.6 billion, plus research and development funding and potential royalty payments.
The Ropes & Gray team included life sciences licensing partner Hannah England and life sciences licensing associates Ian Nilsen and Daniel Freshman and emerging companies and venture capital partner Rajarshi Banerjee.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.